What does this score mean?
The study was published in Science and utilized human obesity samples alongside genetic and animal models. The causal mechanism is strongly supported; however, because therapeutic efficacy targeting this axis has not yet been demonstrated in humans, the clinical confidence score is limited.
What did the study investigate?
It investigated why obesity causes excessive IL-1β production and NLRP3 inflammasome activation in macrophages.
How was it conducted?
The researchers used human obesity samples, cellular experiments, and genetically modified mouse models. The role of the dNTP hydrolase known as SAMHD1 on nucleotide balance and mitochondrial DNA biology was examined.
What was found?
Under conditions of obesity, impairment of SAMHD1 function led to dNTP accumulation. When these nucleotides were transported to the mitochondria, new mtDNA synthesis and an increase in oxidized mtDNA were observed; oxidized mtDNA, in turn, activated the NLRP3 inflammasome, increasing IL-1β production. In SAMHD1-deficient mice, insulin resistance and metabolic dysfunction-associated liver disease increased. Inhibiting the transport of dNTPs into mitochondria reduced inflammasome hyperactivity.
Limitations of the study
Although the mechanistic data are strong, the safety and efficacy of therapeutic targeting have not been demonstrated in humans. NLRP3 plays a role in numerous physiological defense responses; therefore, the benefit-risk balance of chronic inhibition must be separately tested.
What does this mean clinically?
It indicates that low-grade chronic inflammation in obesity is related not only to the amount of adipose tissue, but also to the metabolic reprogramming of macrophages. This axis may be a candidate for future therapies targeting obesity-related inflammation.
What do we not know yet?
It is not yet known whether SAMHD1 or mitochondrial dNTP transport can be safely targeted in humans, whether this would provide clinical benefit independent of weight loss, and what the long-term immune consequences would be.
Source
Liu D, Zhou C, Wang X, et al. Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity. Science. 2026;391(6782):eadq9006. DOI: 10.1126/science.adq9006. Publication date: January 15, 2026.
Related reading: Obesity and Inability to Lose Weight · Mitochondrial Health and Aging
Written and medically reviewed by: Dr. Kerem Çağlayan · All Scientific Research
Detailed evaluation
Mechanistic chain
Obesity → SAMHD1 impairment → dNTP accumulation → mitochondrial new DNA synthesis → increased oxidized mtDNA → NLRP3 activation → increased IL-1β.
Conclusion
This chain presents new drug targets for addressing metabolic inflammation; however, as of today, it has not translated into a clinical treatment protocol.
Medical review note: This content has been prepared for the purpose of interpreting scientific data; it is not a personal diagnosis or treatment recommendation.
